Quick Take #2: Jul 25 Updates!: FDA Denies New Treatment for PTSD, Alcohol Intake Limit Recommendation Ends?, New BBW on SSRIs?, Clozapine REMS Ends!, New Psychedelic for Depression?, and Many More!

Hey All, I'm starting up a new series that will contain several snippets of updates in the psychopharm world. Every month or two I will plan to release an episode where I don't deep dive like normal, but instead cover several important breaking news items that affect psychopharmacology and give my quick take on the news. Some of this will be trial results, FDA updates, interesting papers that were recently published, and anything else I can come up with. Today I have a ton of stuff to tell you about. FDA discussion on BBW on SSRIs for pregnancy, clozapine REMS ends, clozapine semaglutide trial, online ADHD prescription assessment, new psychedelic trial results for treatment resistant depression, change in alcohol intake recommendations, new warning on stimulants, new Alzheimers drug donanemab approved for label change indicating improved safety over competitors, new study on vaping for tobacco cessation, BBW removal for HRT?, FDA decision on brexpiprazole combo for PTSD, and study results on the effects of gabapentin on long-term cognition. I really packed a lot in to this shorter episode. Please have a listen!